November 30th 2023
Which antihypertensive therapy options are most and least effective for patients with migraine? Get details, here.
October 30th 2023
Get details on which migraine treatments are the better option for women who are breastfeeding, and on ones to advise them to avoid.
October 27th 2023
An overview of safe treatment options for migraine attacks that may occur during pregnancy for primary care clinicians, here.
October 20th 2023
Ailiani, director of MedStar Georgetown Headache Center, focuses on optimizing treatment with CGRP inhibitors and where research on PACAP-targeting agents stands now.
September 27th 2023
Your daily dose of the clinical news you may have missed.
For Episodic Migraine, Both OTC and New Oral Prescription Medications Provide Meaningful Pain Relief
In episodic migraine, both traditional oral OTC medications and newly approved classes led to significantly better improvements in pain compared with placebo.
Fatigue Common in Migraine, More Severe in Chronic vs Episodic Disease
Fatigue was positively correlated with frequency, duration, severity and chronicity of migraine episodes and more common among chronic migraineurs, a new study reveals.
Novel Neurostimulation Device Shows Significant Benefit for Migraine
The device from Nexalin Technology outperformed placebo on key measures of pain relief, sleep quality, anxiety, and quality of life.
Primary Care Management of Headache: Part 2
An overview of oral preventive medication options for migraine for primary care clinicians, here.
Daily Dose: Atogepant Associated with Reduction in Monthly Migraine Days
A daily dose of clinical news on Patient Care you may have missed.
Atogepant Reduces Monthly Migraine Days vs Placebo in Persons with Chronic Migraine
The oral gepant reduced monthly migraine days as well as mean monthly use of migraine rescue medication.
BMI vs body fat; menopause and martinis; statin guidelines collide; +2 - The Five for Friday
Is BMI or body fat a better estimate of obesity?; spoiler: older women do drink ETOH; USPSTF vs ACC/AHA; plus no more opioids for LBP and a primer on migraine meds.
Primary Care Management of Headache: Part 1
An overview of common headache conditions and treatments for primary care clinicians, here.
Menstrual Migraine: Common and Disabling
Menstrual migraine is often described as more disabling than non-menstrual migraine. Get an overview and test your knowledge, here.
Where Does Migraine Pain Come From?
The role of the trigeminal nerve and its connection to the brainstem has led to a greater understanding of where migraine pain originates. Expert explains, here.
Are Migraines Different in Women and Men?
Migraine disproportionately affects women, a disparity typically ascribed to hormonal differences. A new study takes a new look at the issue.
Cluster Headache, Migraine Show Strong Links to the Circadian System: Meta-analysis
Cluster headache and migraine are described as "highly circadian at multiple levels," suggesting hypothalamus involvement and potential for new treatments, study authors say.
Daily Dose: Migraine and Pregnancy Complications
Your daily dose of clinical news you may have missed.
Migraine History May Be a Risk Factor for Pregnancy Complications: New Findings
Among women with prepregnancy migraine diagnosis, rates of gestational hypertension and preeclampsia were 28% and 40% higher, respectively, vs women without migraine.
Daily Dose: Women More Seriously Affected by Cluster Headaches
Women May be More Seriously Affected by Cluster Headaches, Suggests New Research
In a study of 874 adults, more women were diagnosed with chronic cluster headache and experienced longer attacks compared with men.
Take a Shot at Migraine: 5 Handy In-office Injectables
Headache is a common complaint in primary care--and sometimes it presents full-blown. You can rescue the patient in distress by keeping 5 common injectables on hand.
Potential IBS-Migraine Association Seen in Nationwide Survey
Individuals with migraine were found more likely to have IBS and IBS was more prevalent in those with migraine; both associations were statistically significant.
Atogepant: Pivotal Phase 3 Study Meets Primary Endpoint for Preventive Treatment of Chronic Migraine
Findings for atogepant from the phase 3 PROGRESS study will form the basis of a submission by AbbVie to FDA for a label expansion in the US.
10 Questions on Migraine Impact, Diagnosis, & Treatment Based on the OVERCOME Study
Lifetime use of opioids for migraine was found to be higher than for triptan medications. Try these 10 questions on other OVERCOME findings.
Unmet Needs in US Migraine Headache Management: OVERCOME Study First Data
Findings on use of acute and preventive migraine therapy continue to reveal gaps with far more patients eligible than the proportions using either type.
Acute Migraine Treatment: A Guide to Medication Options
When choosing a migraine treatment for acute attack relief, the American Headache Society suggests following these steps.
Migraine Linked to Higher Risk of Pregnancy Complications in Preliminary Study
Researchers also found that women with migraine with aura had a higher risk of preeclampsia than those with migraine without aura.
Intranasal Zavegepant for Migraine Meets Coprimary Regulatory Endpoints in Pivotal Phase 3 Trial
Intranasal CGRP inhibitor zavegepant met coprimary regulatory endpoints in pivotal phase 3 trial in adults with migraine; FDA submission planned for Q1 2022.
Migraine Management in Primary Care: 5 SEEDS for Success
Five migraine management essentials for PCPs and headache patients are summarized with the mnemonic SEEDS.
FDA Approves Oral CGRP Inhibitor Atogepant for Prevention of Episodic Migraine
The daily oral CGRP inhibitor is the only agent in the class developed specifically for prevention vs acute treatment of episodic migraine.
FDA Approves Intranasal DHE (Trudhesa) for Acute Migraine Treatment
The DHE nasal spray delivered pain relief at 2 hours for 66% of patients; 93% of those remained pain-free at 24 hours and 86% at 2 days post-dose.
Atogepant for Migraine Prevention Meets Primary, Secondary Endpoints
Oral CGRP inhibitor atogepant significantly reduced monthly headache days and improved daily function in adults with 4 to 14 headaches per month.
Seen in the ED: A Different Kind of Headache
A woman in her 50s who has a history of tension headache presents to the ED with a headache different from any she has had. Mild photophobia is the only finding on physical exam. Your dx?
The Suicide Headache: 5 Cluster Headache Facts You Need to Know
Early diagnosis of cluster headache, commonly considered the most painful condition on earth, is essential to curbing disability; here's what primary care clinicians need to know.
2 Clarke Drive Cranbury, NJ 08512